设为首页 加入收藏

TOP

CAYSTON(aztreonam for inhalation solution)Initial
2016-04-05 12:13:14 来源: 作者: 【 】 浏览:349次 评论:0
  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use CAYSTON safely and effectively. See full prescribing information for CAYSTON.
    CAYSTON ® (aztreonam for inhalation solution)
    Initial U.S. Approval: 1986
    To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with cystic fibrosis (CF) known to have Pseudomonas aeruginosa in the lungs. (1)
    INDICATIONS AND USAGE
    CAYSTON is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia. (1)
    DOSAGE AND ADMINISTRATION
    • Administer one dose (one single use vial and one ampule of diluent) 3 times a day for 28 days. (2.1)
    • Use dose immediately after reconstitution. (2.2)
    • Administer only with the Altera® Nebulizer System. Do not administer with any other type of nebulizer. (2.3)
    DOSAGE FORMS AND STRENGTHS
    • Lyophilized aztreonam (75 mg/vial) (3)
    • Diluent (0.17% sodium chloride): 1 mL/ampule (3)

    CONTRAINDICATIONS

    • Do not administer to patients with a known allergy to aztreonam. (4)

    WARNINGS AND PRECAUTIONS

    • Allergic reaction to CAYSTON was seen in clinical trials. Stop treatment if an allergic reaction occurs. Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (5.1)
    • Bronchospasm has been reported with CAYSTON. Stop treatment if chest tightness develops during nebulizer use. (5.2)
    ADVERSE REACTIONS
    • Common adverse reactions (more than 5%) occurring more frequently in CAYSTON patients are cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain and vomiting. (6.1)

     

    To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD5, option 3 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

    Revised: 5/2014

  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    CAYSTON® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14)].

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs.

  • 2 DOSAGE AND ADMINISTRATION

     

    2.1 Dosing Information

    The recommended dose of CAYSTON for both adults and pediatric patients 7 years of age and older is one single-use vial (75 mg of aztreonam) reconstituted with 1 mL of sterile diluent administered 3 times a day for a 28-day course (followed by 28 days off CAYSTON therapy). Dosage is not based on weight or adjusted for age. Doses should be taken at least 4 hours apart.

    CAYSTON is administered by inhalation using an Altera® Nebulizer System. Patients should use a bronchodilator before administration of CAYSTON.

    2.2 Instructions for CAYSTON Reconstitution

    CAYSTON should be administered immediately after reconstitution. Do not reconstitute CAYSTON until ready to administer a dose.

    Take one amber glass vial containing CAYSTON and one diluent ampule from the carton. To open the glass vial, carefully remove the metal ring by lifting or pulling the tab and remove the gray rubber stopper. Twist the tip off the diluent ampule and squeeze the liquid into the glass vial. Replace the rubber stopper, then gently swirl the vial until contents have completely dissolved.

    The empty vial, stopper, and diluent ampule should be disposed of properly upon completion of dosing.

    2.3 Instructions for CAYSTON Administration

    CAYSTON is administered by inhalation using an Altera Nebulizer System. CAYSTON should not be administered with any other nebulizer. CAYSTON should not be mixed with any other drugs in the Altera Nebulizer Handset.

    CAYSTON is not for intravenous or intramuscular administration.

    Patients should use a bronchodilator before administration of CAYSTON. Short-acting bronchodilators can be taken between 15 minutes and 4 hours prior to each dose of CAYSTON. Alternatively, long-acting bronchodilators can be taken between 30 minutes and 12 hours prior to administration of CAYSTON. For patients taking multiple inhaled therapies, the recommended order of administration is as follows: bronchodilator, mucolytics, and lastly, CAYSTON.

    To administer CAYSTON, pour the reconstituted solution into the handset of the nebulizer system. Turn the unit on. Place the mouthpiece of the handset in your mouth and breathe normally only through your mouth. Administration typically takes between 2 and 3 minutes. Further patient instructions on how to administer CAYSTON are provided in the FDA-approved patient labeling. Instructions on testing nebulizer functionality and cleaning the handset are provided in the Instructions for Use included with the nebulizer system.

  • 3 DOSAGE FORMS AND STRENGTHS

    A dose of CAYSTON consists of a single-use vial of sterile, lyophilized aztreonam (75 mg) reconstituted with a 1 mL ampule of sterile diluent (0.17% sodium chloride). Reconstituted CAYSTON is administered by inhalation.

  • 4 CONTRAINDICATIONS

    CAYSTON is contraindicated in patients with a known allergy to aztreonam.

  • 5 WARNINGS AND PRECAUTIONS

     

    5.1 Allergic Reactions

    Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction to CAYSTON occurs, stop administration of CAYSTON and initiate treatment as appropri

    以下是“全球医药”详细资料
  • Tags: 责任编辑:admin
    】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
    分享到QQ空间
    分享到: 
    上一篇YONDELIS (trabectedin) for inje.. 下一篇CAYSTON(aztreonam for inhalatio..

    相关栏目

    最新文章

    图片主题

    热门文章

    推荐文章

    相关文章

    广告位